Medical Xpress24d
Scientists develop new natural killer cell strategy to target HIV
cells to target and kill the HIV-positive cells that allow the virus to persist. Wistar scientists have labeled this new approach "NuKES": Natural Killer Enhancement Strategy. NK cells are unlike ...
ViiV to trial twice-yearly HIV antibody dosing after Phase IIb success
The company’s Phase IIb trial found the therapy, N6LS, was able to maintain viral loads below a detectable threshold.
EurekAlert!25d
Scientists at The Wistar Institute’s HIV Cure and Viral Diseases Center develop new natural killer cell strategy to target HIV
cells to target and kill the HIV-positive cells that allow the virus to persist. Wistar scientists have labeled this this new approach “NuKES”: Natural Killer Enhancement Strategy. NK cells ...
PipelineReview.com1d
Gilead Presents New HIV Treatment and Cure Research Data at CROI 2025, Including an Investigational Long-Acting, Twice-Yearly Therapy Option
Long-Term Outcomes Reinforce the High Efficacy of Biktarvy ® in People with HIV and HBV Coinfection – – Investigational Long-Acting, Twice-Yearly Treatment Regimen of Len ...
Harnessing Gravity To Create a Low-Cost Device for Rapid Cell Analysis
An AI-enabled device could make flow cytometry affordable and accessible, reports a new study from Rice University.
Seeking Alpha29d
Gilead Sciences: Strong Q4 Results And Huge Progress In HIV
Trodelvy is transitioning to a blockbuster drug, and Gilead is moving to expand the label ... cell therapy. 2025 should be a strong year for Gilead, with the company focusing on strengthening its ...